- Home
- PGY vs CVAC Comparison
PGY vs CVAC Comparison
Compare PGY & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- CVAC
- Stock Information
- Founded
- PGY 2016
- CVAC 2000
- Country
- PGY United States
- CVAC Germany
- Employees
- PGY N/A
- CVAC N/A
- Industry
- PGY Finance: Consumer Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- PGY Finance
- CVAC Health Care
- Exchange
- PGY Nasdaq
- CVAC Nasdaq
- Market Cap
- PGY 863.7M
- CVAC 764.4M
- IPO Year
- PGY N/A
- CVAC 2020
- Fundamental
- Price
- PGY $18.47
- CVAC $5.44
- Analyst Decision
- PGY Strong Buy
- CVAC Buy
- Analyst Count
- PGY 8
- CVAC 3
- Target Price
- PGY $21.44
- CVAC $9.00
- AVG Volume (30 Days)
- PGY 2.0M
- CVAC 2.1M
- Earning Date
- PGY 08-08-2025
- CVAC 08-14-2025
- Dividend Yield
- PGY N/A
- CVAC N/A
- EPS Growth
- PGY N/A
- CVAC N/A
- EPS
- PGY N/A
- CVAC 0.87
- Revenue
- PGY $1,076,961,000.00
- CVAC $566,039,775.00
- Revenue This Year
- PGY $20.61
- CVAC N/A
- Revenue Next Year
- PGY $13.33
- CVAC $24.04
- P/E Ratio
- PGY N/A
- CVAC $6.34
- Revenue Growth
- PGY 23.69
- CVAC 787.60
- 52 Week Low
- PGY $8.20
- CVAC $2.37
- 52 Week High
- PGY $19.20
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- PGY 64.13
- CVAC 68.03
- Support Level
- PGY $18.10
- CVAC $4.07
- Resistance Level
- PGY $19.04
- CVAC $5.58
- Average True Range (ATR)
- PGY 0.83
- CVAC 0.20
- MACD
- PGY -0.06
- CVAC 0.07
- Stochastic Oscillator
- PGY 79.08
- CVAC 83.08
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.